Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?-the results of the Pan-PPAR Lanifibranor trial.
作者信息
Gastaldelli Amalia
机构信息
Cardiometabolic Risk Unit, Institute of Clinical Physiology, CNR, Pisa, Italy.
出版信息
Hepatobiliary Surg Nutr. 2022 Jun;11(3):481-484. doi: 10.21037/hbsn-21-569.
Abstract
摘要
相似文献
1
Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?-the results of the Pan-PPAR Lanifibranor trial.为有效治疗非酒精性脂肪性肝炎，是否有必要针对不同器官的脂质代谢进行治疗？——泛PPAR激动剂lanifibranor试验的结果
Hepatobiliary Surg Nutr. 2022 Jun;11(3):481-484. doi: 10.21037/hbsn-21-569.
2
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.随机、对照试验研究泛 PPAR 激动剂 Lanifibranor 在 NASH 中的作用。
N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.
3
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.全PPAR激动剂拉尼非诺能改善实验性晚期慢性肝病中的门静脉高压和肝纤维化。
J Hepatol. 2021 May;74(5):1188-1199. doi: 10.1016/j.jhep.2020.11.045. Epub 2020 Dec 2.
4
The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.全过氧化物酶体增殖物激活受体激动剂 lanifibranor 可减少系统性硬皮病转基因小鼠模型的肺纤维化发展，并减轻心肺表现。
Arthritis Res Ther. 2021 Sep 6;23(1):234. doi: 10.1186/s13075-021-02592-x.
5
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.一项随机、双盲、安慰剂对照、多中心、剂量范围、概念验证、为期 24 周的兰尼非班治疗非酒精性脂肪性肝炎成年患者的研究：NATIVE 研究的设计。
Contemp Clin Trials. 2020 Nov;98:106170. doi: 10.1016/j.cct.2020.106170. Epub 2020 Oct 8.
6
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.在 GAN 饮食诱导的肥胖和活检证实的 NASH 小鼠模型中，司美格鲁肽、利那芦醇和饮食干预的肝保护作用。
Clin Transl Sci. 2022 May;15(5):1167-1186. doi: 10.1111/cts.13235. Epub 2022 Feb 24.
7
Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.人类肝脏体外模型揭示了 PPAR 激动剂对非酒精性脂肪性肝炎的不同治疗潜力。
Cell Biol Toxicol. 2021 Apr;37(2):293-311. doi: 10.1007/s10565-020-09544-2. Epub 2020 Jul 1.
8
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.新型吲哚磺酰胺过氧化物酶体增殖物激活受体（PPAR）α/γ/δ三重激动剂的设计、合成与评价：Lanifibranor，一种新型抗纤维化临床候选药物的发现。
J Med Chem. 2018 Mar 22;61(6):2246-2265. doi: 10.1021/acs.jmedchem.7b01285. Epub 2018 Feb 27.
9
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.非酒精性脂肪性肝病（NAFLD）/非酒精性脂肪性肝炎（NASH）相关肝纤维化：机制、治疗与预防
Ann Transl Med. 2021 Apr;9(8):729. doi: 10.21037/atm-20-4354.
10
The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice.过氧化物酶体增殖物激活受体 α 的转录抑制活性对于预防小鼠肝纤维化是必需且充分的。
Hepatology. 2014 Nov;60(5):1593-606. doi: 10.1002/hep.27297. Epub 2014 Oct 1.
引用本文的文献
1
Pathological Evolution and Internal Medicine Management of Nonalcoholic Fatty Liver Disease (NAFLD) in the Era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).代谢功能障碍相关脂肪性肝病（MASLD）时代非酒精性脂肪性肝病（NAFLD）的病理演变与内科管理
Cureus. 2025 Jun 29;17(6):e86963. doi: 10.7759/cureus.86963. eCollection 2025 Jun.
2
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development.MAFLD大流行：药物治疗方法开发的最新进展
Curr Issues Mol Biol. 2024 Jun 21;46(7):6300-6314. doi: 10.3390/cimb46070376.
3
CRISPR-edited hepatic organoids as drug screening platform for non-alcoholic fatty liver disease.经CRISPR编辑的肝类器官作为非酒精性脂肪性肝病的药物筛选平台
Hepatobiliary Surg Nutr. 2023 Aug 1;12(4):593-594. doi: 10.21037/hbsn-23-247. Epub 2023 Jul 6.
4
From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications.从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病：定义、病理生理基础及心血管影响
Biomedicines. 2023 Mar 13;11(3):883. doi: 10.3390/biomedicines11030883.
本文引用的文献
1
Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis.脂肪组织胰岛素抵抗和脂质组改变作为非酒精性脂肪性肝炎的特征因素。
Eur J Clin Invest. 2022 Mar;52(3):e13695. doi: 10.1111/eci.13695. Epub 2021 Dec 7.
2
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.随机、对照试验研究泛 PPAR 激动剂 Lanifibranor 在 NASH 中的作用。
N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205.
3
New targets for NAFLD.非酒精性脂肪性肝病的新靶点
JHEP Rep. 2021 Aug 8;3(6):100346. doi: 10.1016/j.jhepr.2021.100346. eCollection 2021 Dec.
4
PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.过氧化物酶体增殖物激活受体-γ 诱导内脏脂肪和脂联素水平的变化与 NASH 患者肝脂肪变性的改善相关。
Liver Int. 2021 Nov;41(11):2659-2670. doi: 10.1111/liv.15005. Epub 2021 Jul 21.
5
Liver-targeting drugs and their effect on blood glucose and hepatic lipids.肝靶向药物及其对血糖和肝脂的影响。
Diabetologia. 2021 Jul;64(7):1461-1479. doi: 10.1007/s00125-021-05442-2. Epub 2021 Apr 20.
6
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.全PPAR激动剂拉尼非诺能改善实验性晚期慢性肝病中的门静脉高压和肝纤维化。
J Hepatol. 2021 May;74(5):1188-1199. doi: 10.1016/j.jhep.2020.11.045. Epub 2020 Dec 2.
7
Identification of Lineage-Specific Transcription Factors That Prevent Activation of Hepatic Stellate Cells and Promote Fibrosis Resolution.鉴定阻止肝星状细胞激活并促进纤维化消退的谱系特异性转录因子。
Gastroenterology. 2020 May;158(6):1728-1744.e14. doi: 10.1053/j.gastro.2020.01.027. Epub 2020 Jan 23.
8
Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction.肥胖患者肝脏中 PPAR-γ mRNA 表达的上调：对 SREBP-1c 诱导的附加加强的脂肪生成机制。
J Clin Endocrinol Metab. 2011 May;96(5):1424-30. doi: 10.1210/jc.2010-2129. Epub 2011 Feb 16.
9
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta.降血脂药物、多不饱和脂肪酸和类二十烷酸是过氧化物酶体增殖物激活受体α和δ的配体。
Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4312-7. doi: 10.1073/pnas.94.9.4312.
Zotero 插件